Loading...

FITC anti-mouse CD69 Antibody

Pricing & Availability
Clone
H1.2F3 (See other available formats)
Regulatory Status
RUO
Other Names
Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
h1.2f3
PMA-stimulated (6 hours) splenocytes stained with H1.2F3 FITC
  • h1.2f3
    PMA-stimulated (6 hours) splenocytes stained with H1.2F3 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
104505 50 µg 83 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104506 500 µg 293 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse dendritic epidermal T cell line Y245
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: in vitro T cell and NK cell activation1-3, immunohistochemistry4,5, and immunoprecipitation1.

This antibody has been characterized in the literature as containing a lambda (?) light chain.

Application References

(PubMed link indicates BioLegend citation)
  1. Yokoyama WM, et al. 1988. J. Immunol. 141:369. (IP)
  2. Sobel ES, et al. 1993. J. Immunol. 150:673.
  3. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  4. Zhou X, et al. 2005. J. Biol. Chem. 280:31240. (IHC)
  5. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC)
  6. Lawson BR, et al. 2007. J. Immunol. 178:5366.
  7. Lee JW, et al. 2006. Nature Immunol. 8:181.
  8. Epardaud M, et al. 2008. Cancer Res. 15:2972. PubMed
  9. Jordan JM, et al. 2008. 76:3717. PubMed
  10. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  11. Ishikawa C, et al. 2013. Biochim Biophys Acta. 167:99. PubMed
Product Citations
  1. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  2. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  3. Cordero-Reyes A, et al. 2016. J Am Heart Assoc. 5: 002484. PubMed
  4. Song Y, et al. 2020. Front Immunol. 11:558143. PubMed
  5. van Vloten JP, et al. 2022. J Immunother Cancer. 10:. PubMed
  6. Buxadé M, et al. 2018. J Exp Med. 215:2901. PubMed
  7. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  8. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  9. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  10. de Mingo Pulido , et al. 2021. Immunity. 54(6):1154-1167.e7. PubMed
  11. Byun JK, et al. 2020. Molecular Cell. 80(4):592-606.e8. PubMed
  12. Burrack AL, et al. 2019. Cell Rep. 28:2140. PubMed
  13. Chen J et al. 2018. Cell reports. 25(12):3393-3404 . PubMed
  14. Álvaro de Mingo Pulido et al. 2018. Cancer cell. 33(1):60-74 . PubMed
  15. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  16. Liu Q, et al. 2021. Cell Death Dis. 12:240. PubMed
  17. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  18. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  19. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  20. Hasezaki T, et al. 2020. Sci Rep. 10:6969. PubMed
  21. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  22. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  23. Bhattacharjee P, et al. 2018. Sci Rep. 13:e0199785. PubMed
  24. Pereira JL, et al. 2021. Transl Oncol. 14:101125. PubMed
  25. Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed
  26. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  27. Mandrup OA, et al. 2021. Commun Biol. 310:4. PubMed
  28. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  29. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  30. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  31. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  32. Uhde A, et al. 2016. PLoS One. 11: 0161883. PubMed
  33. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  34. Fontinha D, et al. 2015. PLoS One. 10: 0142540. PubMed
  35. Baier FA, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:745. PubMed
  36. Stanford S, et al. 2012. Proc Natl Acad Sci U S A. 109:13972. PubMed
  37. Haile S, et al. 2014. Cancer Immunol Res. 2:610. PubMed
  38. White C, et al. 2015. J Immunol. 194:697. PubMed
  39. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  40. Li C, et al. 2020. Immunity. 52(1):201-202. PubMed
  41. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  42. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  43. Lim S, et al. 2016. PLoS One. 11: 0155689. PubMed
  44. XS R, et al. 2015. Diabetes. 64 90. PubMed
  45. Moore MJ et al. 2018. eLife. 7 pii: e33057. PubMed
  46. Kang X, et al. 2022. J Immunol Res. 2022:8118577. PubMed
  47. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  48. Tao F, et al. 2013. Biochem Pharmacol. 85:798. PubMed
  49. Zhang W, et al. 2019. Mar Drugs. 0.845138889. PubMed
  50. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  51. Ma K, et al. 2022. iScience. 25:104347. PubMed
  52. Riva A, et al. 2017. PLoS One.. 10.1371/journal.pone.0181964. PubMed
  53. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  54. Wang L, et al. 2021. Sci Adv. 7:eabj4796. PubMed
  55. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  56. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  57. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  58. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  59. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  60. Rui J, et al. 2021. Nat Commun. 12:5074. PubMed
  61. Song TY, et al. 2021. Nat Commun. 12:7003. PubMed
  62. Klezovich-Bénard M, et al. 2012. PLoS One. 8:e1002481. PubMed
  63. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  64. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  65. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  66. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  67. Han J, et al. 2015. Cancer Res . 75: 5273 - 5282. PubMed
  68. Kuhn NF et al. 2019. Cancer cell. 35(3):473-488 . PubMed
  69. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_313108 (BioLegend Cat. No. 104505)
AB_313109 (BioLegend Cat. No. 104506)

Antigen Details

Structure
C-type lectin, 27/33 kD
Distribution

Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets

Function
Lymphocyte activation
Cell Type
B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Testi R, et al. 1994. Immunol. Today 15:479.
3. Moretta A, et al. 1991. J. Exp. Med. 174:1393.
4. Yokoyama WM, et al. 1988. J. Immunol. 141:369.

Gene ID
12515 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 3    Revision Date: 04.18.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account